Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Loft M, Lok SW, De Boer R, Malik L, Greenberg S, Yeo B, Anton A, Nottage M, Wong V, Nott L, Collins IM, Torres J, Barnett F, Lombard JM, Gibbs P, Gately L. Loft M, et al. Among authors: lok sw. Breast Cancer Res Treat. 2023 Feb;198(1):67-74. doi: 10.1007/s10549-022-06856-1. Epub 2023 Jan 9. Breast Cancer Res Treat. 2023. PMID: 36624321
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y, Lok SW, Gibbs P, De Boer R, Yeo B, Greenberg S, Barnett F, Knott L, Richardson G, Wong R, Nottage M, Collins IM, Torres J, Lombard J, Johns J, Harold M, Malik L. Kanjanapan Y, et al. Among authors: lok sw. Breast Cancer Res Treat. 2020 Nov;184(1):87-95. doi: 10.1007/s10549-020-05825-w. Epub 2020 Aug 10. Breast Cancer Res Treat. 2020. PMID: 32779037
Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study.
Tung I, Moldovan C, Wong V, De Boer R, Yeo B, Malik L, Greenberg S, Anton A, Nott L, Barnett F, Collins IM, Lombard J, Nottage M, Sahu A, Torres J, Gibbs P, Lok SW. Tung I, et al. Among authors: lok sw. Clin Breast Cancer. 2022 Oct;22(7):e764-e772. doi: 10.1016/j.clbc.2022.07.005. Epub 2022 Jul 14. Clin Breast Cancer. 2022. PMID: 35941066
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.
Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, Uccellini A, Hong W, Gibbs P, Lok SW. Wong V, et al. Among authors: lok sw. Clin Breast Cancer. 2022 Dec;22(8):792-800. doi: 10.1016/j.clbc.2022.08.011. Epub 2022 Aug 30. Clin Breast Cancer. 2022. PMID: 36151018
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
Burge M, Semira C, Lee B, Lee M, Kosmider S, Wong R, Shapiro J, Ma B, Dean AP, Zimet AS, Steel SA, Lok SW, Torres J, Eastgate M, Wong HL, Gibbs P. Burge M, et al. Among authors: lok sw. Clin Colorectal Cancer. 2018 Sep;17(3):e593-e599. doi: 10.1016/j.clcc.2018.05.009. Epub 2018 Jun 1. Clin Colorectal Cancer. 2018. PMID: 29958812
34 results